

## **BIND Therapeutics Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 12-Apr-2013

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 9

[Return to Table of Contents](#)

# BIND Therapeutics Inc

## COMPANY OVERVIEW

Company Name	BIND Therapeutics Inc
Parent Company Name	BIND Therapeutics Inc
Website	<a href="http://www.bindbio.com/">http://www.bindbio.com/</a>
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	0
Number of Patents as Owner	15
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Cancer, Solid tumor, Inflammatory disease, Cardiovascular disease, Prostate tumor, Breast tumor, Lung tumor, Asthma, Bladder cancer, Crohns disease, Dermatitis, Inflammatory bowel disease, Non-small-cell lung cancer, Osteoarthritis, Ulcerative colitis, Uterine cervix tumor
Key Target-based Actions	Glutamate carboxypeptidase II inhibitor, Unspecified protein kinase inhibitor, CD40 ligand, Epidermal growth factor ligand, Estrogen receptor agonist, GM-CSF ligand, Insulin-like growth factor ligand, Integrin alpha-V/beta-3 modulator, Interleukin-2 ligand, PDGF ligand, Somatostatin ligand, mTOR
Key Technologies	Nanoparticle formulation, Small molecule therapeutic, Intravenous formulation, Nanoparticle formulation injectable, Controlled release formulation, Quick release formulation, Formulation preservation, PEGylated formulation, Suspension, Emulsion formulation

## COMPANY PROFILE

### SUMMARY

BIND Therapeutics (previously BIND Biosciences Inc), founded in 2006, is a biopharmaceutical company specializing in the development of therapeutic targeted nanoparticles. In April 2013, BIND Biosciences changed its name to BIND Therapeutics.

### R&D GRANTS

In October 2007, the National Institutes of Standards and Technology awarded BIND a 3-year \$2 million grant to further develop a high-throughput platform for its targeted nanoparticle technology.

Also in October 2007, the NCI awarded BIND a 6-month, \$0.15 million Phase I SBIR grant to develop a targeted therapy for hormone refractory prostate cancer.

### FINANCIAL

In October 2011, BIND secured total proceeds of \$47.25 million through a \$22 million series D financing from RUSNANO and additional funding up to \$25.25 million from its investors.

In June 2010, the company secured \$12.4 million in a series C-1 financing.

In January 2010, the company secured \$11 million in a series C financing.

In November 2007, BIND was to raise \$16 million from a series B financing. The funding would be used to advance the company's preclinical pipeline to clinical trials.

### EARLY R&D/TECHNOLOGY UPDATES

IND's Medicinal Nanoengineering platform aims to produce targeted nanoparticles with unprecedented control over drug properties to maximize trafficking to disease sites, leading to superior efficacy while minimizing toxicities.

[Return to Table of Contents](#)




By December 2007, BIND had been focusing on nanoparticles-targeting therapeutic for cancer, cardiovascular diseases and inflammatory diseases; in June 2010, the company planned to advance its second product into clinical development in 2011.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	0	3
Cardiovascular disease	1	0	1
Inflammatory disease	1	0	1

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	4

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	2	0	0	0	2
Drug - Development/Commercialization License	2	0	0	0	2

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	2	3
Genitourinary disease	1	1
Respiratory disease	1	1
Andrology	1	1

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 2	2	2
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	6	0	6
Gastrointestinal disease	3	0	3
Genitourinary disease	8	0	8
Hematological disease	2	0	2
Andrology	8	0	8
Immune disorder	3	0	3
Musculoskeletal disease	2	0	2
Neoplasm	10	0	10
Ocular disease	1	0	1
Neurological disease	4	0	4
Respiratory disease	4	0	4
Infectious disease	2	0	2
Inflammatory disease	2	0	2
Gynecology and obstetrics	7	0	7
Dermatological disease	2	0	2

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics

<b>Drug Name</b>	polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	BIND Therapeutics Inc
<b>Active Companies</b>	BIND Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Glutamate carboxypeptidase II inhibitor
<b>Other Actions</b>	Cell cycle inhibitor, Microtubule inhibitor
<b>Technologies</b>	Nanoparticle formulation injectable, Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	04-Apr-2013

### targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics

<b>Drug Name</b>	targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	BIND Therapeutics Inc
<b>Active Companies</b>	BIND Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anti-inflammatory, Unspecified drug target
<b>Technologies</b>	Nanoparticle formulation, Small molecule therapeutic
<b>Last Change Date</b>	03-Apr-2013

[Return to Table of Contents](#)



### targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics

<b>Drug Name</b>	targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	BIND Therapeutics Inc
<b>Active Companies</b>	BIND Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cardiovascular disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Cardiovascular agent
<b>Technologies</b>	Nanoparticle formulation, Small molecule therapeutic
<b>Last Change Date</b>	03-Apr-2013

### molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics

<b>Drug Name</b>	molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	BIND Therapeutics Inc
<b>Active Companies</b>	BIND Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Nanoparticle formulation, Small molecule therapeutic
<b>Last Change Date</b>	08-Apr-2013

[Return to Table of Contents](#)



kinase inhibitor (Accurin nanomedicine, solid tumors), BIND Therapeutics/Amgen

Drug Name	kinase inhibitor (Accurin nanomedicine, solid tumors), BIND Therapeutics/Amgen
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	Amgen Inc, BIND Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Solid tumor
Target-based Actions	Unspecified protein kinase inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Nanoparticle formulation, Small molecule therapeutic
Last Change Date	05-Apr-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

